By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ocular Therapeutix, Inc. 

204 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-895-3235 Fax: 781-895-3236


SEARCH JOBS


Industry
Biotechnology






Company News
Ocular Therapeutix (OCUL) Strengthens Executive Management Team With The Appointment Of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., As Chief Medical Officer 1/11/2016 12:44:08 PM
Ocular Therapeutix (OCUL) Announces Encouraging Top-Line Results From Exploratory Phase 2 Trial For DEXTENZA In Patients With Inflammatory Dry Eye Disease 12/14/2015 1:15:12 PM
Ocular Therapeutix (OCUL) Announces FDA Acceptance Of NDA Filing For DEXTENZA For The Treatment Of Post-Surgical Ocular Pain 12/9/2015 8:45:29 AM
Ocular Therapeutix (OCUL) To Present At The Piper Jaffray 27th Annual Healthcare Conference 11/25/2015 7:39:09 AM
Ocular Therapeutix (OCUL) Begins Enrollment In Its Second Phase III Clinical Trial For DEXTENZA For The Treatment Of Allergic Conjunctivitis 11/24/2015 9:55:07 AM
Ora Release: Ora-CAC Model Delivers Successful Phase III Data For Ocular Therapeutix (OCUL)'s DEXTENZA (OTX-DP) For Treatment Of Allergic Conjunctivitis 11/12/2015 10:38:10 AM
Ocular Therapeutix (OCUL) Reports Third Quarter 2015 Financial Results 11/11/2015 10:40:01 AM
Ocular Therapeutix (OCUL) Expands Its Board Of Directors With The Election Of Industry Leader W. James O’Shea 11/10/2015 11:07:37 AM
Ocular Therapeutix (OCUL) To Report Third Quarter 2015 Financial Results 11/4/2015 10:42:09 AM
Ocular Therapeutix (OCUL)'s OTX-TP Can't Match Timolol in Phase IIb Glaucoma Study 10/23/2015 10:25:58 AM
12345678
//-->